This legislation aims to increase financial support for cancer research conducted by the National Cancer Institute (NCI), intending to better align investment with cancer mortality rates. For each fiscal year from 2026 through 2030, the bill appropriates an amount equal to 25 percent of the NCI's total appropriation for fiscal year 2022 , to be available until expended. These additional funds are explicitly designated to supplement, not replace, existing NCI appropriations, reinforcing the institute's role in advancing medical breakthroughs. The bill also mandates a comprehensive study on the causes of cancer drug shortages , to be conducted by the Secretary of Health and Human Services through the Commissioner of Food and Drugs. This study will investigate factors such as economic reasons, supply chain failures, delays in drug development and approval, and the availability of generic or biosimilar drugs. A report detailing the study's findings and offering recommendations to address these shortages must be submitted to Congress within one year of the Act's enactment.